Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $131.86 Average PT from Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have earned an average rating of “Buy” from the seven analysts that are currently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $131.86.

A number of analysts have recently weighed in on the stock. Truist Financial reaffirmed a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st.

Hedge Funds Weigh In On Lantheus

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC lifted its stake in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the last quarter. UMB Bank n.a. increased its position in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the period. GAMMA Investing LLC increased its position in Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after acquiring an additional 146 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Lantheus in the 3rd quarter valued at approximately $25,000. Finally, CWM LLC increased its position in Lantheus by 63.0% in the 3rd quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock valued at $82,000 after acquiring an additional 290 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 2.0 %

Shares of Lantheus stock opened at $91.58 on Tuesday. The company has a 50 day moving average of $89.64 and a 200-day moving average of $99.77. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The company has a market cap of $6.37 billion, a PE ratio of 15.24 and a beta of 0.46.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.